Equine and ovine F(ab) or F(ab)2 polyvalent antivenoms remain standard care; monoclonal antibody and small-molecule (varespladib) approaches are next-generation.
Equine and ovine F(ab) or F(ab)2 polyvalent antivenoms remain standard care; monoclonal antibody and small-molecule (varespladib) approaches are next-generation.